Buy LGVN by Nov 8, 2026.

I've been looking into $LGVN ahead of the ELPIS II results expected this August. The setup looks interesting: \- ELPIS II is a randomized Phase 2b trial with 40 children with HLHS. \- Previous ELPIS I data showed 100% transplant-free survival in 10 treated patients up to 5 years, although it was a very small open-label study. \- The latest DMC review found no new safety issues and recommended completing the trial. \- FDA recently indicated that RVEF alone won't …